Share Market Newspaper

Osteogenesis Imperfecta Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Sanofi, Novosteo, Amgen, Mereo BioPharma, Amgen, UCB, Adge Pharmaceuticals, Keros Therapeutics

 Breaking News
  • No posts were found

Osteogenesis Imperfecta Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Sanofi, Novosteo, Amgen, Mereo BioPharma, Amgen, UCB, Adge Pharmaceuticals, Keros Therapeutics

September 12
01:22 2023
Osteogenesis Imperfecta Market Anticipating Remarkable Growth by 2032, Insights by DelveInsight | Sanofi, Novosteo, Amgen, Mereo BioPharma, Amgen, UCB, Adge Pharmaceuticals, Keros Therapeutics
Delveinsight Business Research LLP
As per DelveInsight, the Osteogenesis Imperfecta Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Osteogenesis Imperfecta and the launch of new therapies in the market.

DelveInsight’s “Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Osteogenesis Imperfecta market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Osteogenesis Imperfecta drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Osteogenesis Imperfecta treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Osteogenesis Imperfecta: An Overview

Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the development of bones. People with this condition have bones that break easily, often from little or no trauma. However, the severity is different from person to person. Multiple fractures are common and, in severe cases, can even occur before birth. Milder cases may involve only a few fractures over a person’s lifetime. In adulthood, people with OI may also have dental problems (dentinogenesis imperfecta) and hearing loss. Other features may include muscle weakness, loose joints, and skeletal malformations.

Depending on the genetic cause, OI may be inherited in an autosomal dominant (more commonly) or autosomal recessive pattern. Diagnosis is based on the symptoms, clinical exam, and imaging studies and may be confirmed by the results of genetic testing. Treatment is focused on managing the symptoms and aims to decrease the number of fractures and disabilities.

There are at least 19 recognized forms of osteogenesis imperfecta, designated type I through type XIX. Several types are distinguished by their signs and symptoms, although their characteristic features overlap. Increasingly, genetic causes are used to define rarer forms of osteogenesis imperfecta. Type I (also known as classic non-deforming osteogenesis imperfecta with blue sclerae) is the mildest form of osteogenesis imperfecta. Type II (also known as perinatally lethal osteogenesis imperfecta) is the most severe. Other types of this condition, including types III (progressively deforming osteogenesis imperfecta) and IV (common variable osteogenesis imperfecta with normal sclerae), have signs and symptoms that fall somewhere between these two extremes.

Osteogenesis Imperfecta Market Key Facts

  • As per the article by Palomo et al. (2017), osteogenesis imperfecta affects approximately 1 in 10,000–20,000 births. It is a genetically heterogeneous skeletal dysplasia with higher mortality than the general population.

  • According to Marini et al. (2017), studies from Europe and the United States have found a birth prevalence of osteogenesis imperfecta of 0.3–0.7 per 10,000 births. Population surveys in countries with comprehensive medical databases, estimated a prevalence of about 0.5 per 10,000 individuals, with most having phenotypically milder osteogenesis imperfecta type I and type IV.

  • As per the study conducted by Lindahl et al. (2015), the COL1A1 and COL1A2 genes were analyzed in the families of what was estimated to be more than 95% of children with Osteogenesis Imperfecta, and an alteration was found in 87%. The prevalence of Osteogenesis Imperfecta Types I, III, and IV was determined to be 7.4/100,000, which is higher than in many previous studies but close to the figure experts in the field have anticipated. Notably, 32% of Type I Osteogenesis Imperfecta was due to qualitative mutations.

Osteogenesis Imperfecta Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Osteogenesis Imperfecta pipeline therapies. It also thoroughly assesses the Osteogenesis Imperfecta market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Osteogenesis Imperfecta drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Osteogenesis Imperfecta Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Osteogenesis Imperfecta epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Osteogenesis Imperfecta epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Osteogenesis Imperfecta Epidemiology, Segmented as –

  • Total Prevalence of Osteogenesis Imperfecta

  • Type-specific Prevalence of Osteogenesis Imperfecta

  • Gene-specific Prevalence of Osteogenesis Imperfecta

  • Diagnosed and Treatable Cases of Osteogenesis Imperfecta 

Osteogenesis Imperfecta Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Osteogenesis Imperfecta market or expected to be launched during the study period. The analysis covers the Osteogenesis Imperfecta market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Osteogenesis Imperfecta drugs based on their sale and market share.

The report also covers the Osteogenesis Imperfecta pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Osteogenesis Imperfecta companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Osteogenesis Imperfecta Market Will Evolve and Grow by 2032 @

Osteogenesis Imperfecta Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Osteogenesis imperfecta (OI). Currently, Mereo BioPharma is leading the therapeutics market with its Osteogenesis imperfecta (OI) drug candidates in the most advanced stage of clinical development.

Osteogenesis Imperfecta Companies Actively Working in the Therapeutics Market Include

  • Sanofi

  • Novosteo

  • Amgen

  • Mereo BioPharma

  • Amgen/UCB

  • Adge Pharmaceuticals

  • Keros Therapeutics

And Many Others

Emerging and Marketed Osteogenesis Imperfecta Therapies Covered in the Report Include:

  • Setrusumab: Mereo BioPharma

  • EVENITY (romosozumab): Amgen Pharmaceuticals

  • SAR439459: Sanofi

And Many More

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Osteogenesis Imperfecta Competitive Intelligence Analysis

4. Osteogenesis Imperfecta Market Overview at a Glance

5. Osteogenesis Imperfecta Disease Background and Overview

6. Osteogenesis Imperfecta Patient Journey

7. Osteogenesis Imperfecta Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Osteogenesis Imperfecta Treatment Algorithm, Current Treatment, and Medical Practices

9. Osteogenesis Imperfecta Unmet Needs

10. Key Endpoints of Osteogenesis Imperfecta Treatment

11. Osteogenesis Imperfecta Marketed Therapies

12. Osteogenesis Imperfecta Emerging Drugs and Latest Therapeutic Advances

13. Osteogenesis Imperfecta Seven Major Market Analysis

14. Attribute Analysis

15. Osteogenesis Imperfecta Market Outlook (In US, EU5, and Japan)

16. Osteogenesis Imperfecta Companies Active in the Market

17. Osteogenesis Imperfecta Access and Reimbursement Overview

18. KOL Views on the Osteogenesis Imperfecta Market

19. Osteogenesis Imperfecta Market Drivers

20. Osteogenesis Imperfecta Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Vulvodynia Market

“Vulvodynia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Vulvodynia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Vulvodynia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States